Myriad Genetics Profit Margin

Myriad Genetics (MYGN) currently reports a profit margin of -13.96% as of June 2026. That compares with -47.45% in the prior-year period — up 70.6% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore Myriad Genetics's profit margin history and peer comparisons.

Myriad Genetics's profit margin increased from -47.45% to -13.96% — a 70.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myriad Genetics's profit margin of -13.96% is lower than the Healthcare sector average of 14.41%. That is roughly 196.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Myriad Genetics's current -13.96% should be judged against Healthcare norms (sector average: 14.41%) and against MYGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -13.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Myriad Genetics, and consider following MYGN for alerts when major investors trade the stock.